EU MDR Annex VIII Classification

Annex VIII classification is governed by the manufacturer's intended purpose. Do not start with a market category, product family, or competitor class; start with the actual claims, instructions for use, clinical context, target users, patient population, body contact, and whether the item is a device, an accessory, an Annex XVI product, or software.

Record the facts that Annex VIII uses: whether the device is non-invasive, invasive through a body orifice, surgically invasive, implantable, active, or software; whether it contacts injured skin or mucous membrane; the relevant body site; whether substances are absorbed or locally dispersed; and the duration of continuous use.

For non-invasive devices, Annex VIII starts from class I unless a more specific rule applies, such as channeling or storing blood or body liquids, modifying biological or chemical composition, direct contact with human cells or embryos, or contact with injured skin or mucous membrane.

For invasive and implantable devices, duration and route into the body often decide the rule. Body-orifice devices are treated separately from surgically invasive devices, and implantable or long-term surgically invasive devices generally start higher before exceptions and class III triggers are considered.

For active devices, document the energy or substance pathway. Annex VIII contains separate rules for active therapeutic devices, active diagnostic and monitoring devices, software, devices that administer or remove medicinal products or body liquids, and residual active devices.

Software needs two separate checks. First, decide whether it is medical device software: MDCG 2019-11 states that software must have a medical purpose on its own to qualify as medical device software, although software that drives or influences a hardware medical device can still affect the hardware device's classification.

If the software is medical device software, Rule 11 classifies software that provides information used for diagnostic or therapeutic decisions as class IIa, with escalation to class IIb or III when the decision impact could involve serious deterioration, surgical intervention, death, or irreversible deterioration. Software intended to monitor physiological processes is class IIa unless it monitors vital physiological parameters where variations could create immediate danger, in which case it is class IIb. Other software is class I unless another Annex VIII rule applies.

Do not treat every digital health workflow as Rule 11 software. MDCG 2019-11 distinguishes simple storage, archiving, communication, search, and non-medical operational software from software that processes, analyses, creates, or modifies medical information for a medical intended purpose.

The class is not just a label. Article 52 links class III, IIb, IIa, and certain class I devices to different conformity assessment procedures in Annexes IX to XI. MDCG 2021-24 explains the practical result: all devices need MDR obligations such as GSPR compliance, technical documentation, post-market surveillance documentation, vigilance, CE marking where applicable, UDI, and registration, but notified body involvement increases with the device class.

Class I devices generally use manufacturer declaration after technical documentation is drawn up, but sterile class I, measuring class I, and reusable surgical instruments have limited notified body involvement for those specific aspects. Class IIa, IIb, and III devices require notified body assessment under the applicable Article 52 route, with representative technical documentation sampling for many class IIa and IIb devices and more intensive assessment for higher-risk classes.

When a notified body is required, record the chosen conformity assessment route, the device group or category used for any representative sampling, and whether special MDR procedures apply, such as class III custom-made implantable provisions or clinical evaluation consultation for class III implantable devices and class IIb active devices that administer or remove medicinal products.

The classification rationale should be reproducible by a reviewer who has not followed the product history. It should show the claims and use context assessed, the Annex VIII rules considered, the rule selected, the higher-class resolution where rules overlap, and the conformity assessment consequences.

Keep the classification memo with the technical documentation because MDCG 2021-24 links the technical documentation to the device risk class and the justification for the Annex VIII rule applied.